Hansa Biopharma — Maj 2023
-
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle
Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.
Yahoo Finance (finance.yahoo.com)
-
UPDATE 1-FDA advisers weigh Sarepta's Duchenne gene therapy
UPDATE 4-US FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approval
Advisers to the U.S. Food and Drug Administration on Friday narrowly recommended that the agency grant accelerated approval to Sarepta Therapeutics Inc's first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD). Tabassum Ahsan, chair of the panel and vice president of cell therapy operations at California's City of Hope, said she was "very much on the edge" but ended up voting yes.
Yahoo Finance (finance.yahoo.com)
-
Aktien er pt. paused. Det skal vi lige huske.
-
-
FDA presentation has concluded. Q&A now. https://twitter.com/maxonwifi/status/1657090567497474050
-
Tak exitnu...Jeg følger Q&A. Umiddelbart ser det ikke godt ud for det videre forløb for Sarepta.
-
FDA advisors say the benefit-risk profile of SRP-9001 DOES support accelerated approval. The votes:
Yes: 8No: 6
-
FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind